Evidence map›Paper›PMID 35207446›Full record

ArticleLife (Basel, Switzerland)2022

Reliable and Scalable SARS-CoV-2 qPCR Testing at a High Sample Throughput: Lessons Learned from the Belgian Initiative.

Steven Van Vooren, James Grayson, Marc Van Ranst, Elisabeth Dequeker, Lies Laenen, Reile Janssen, Laurent Gillet, Fabrice Bureau, Wouter Coppieters, Nathalie Devos and 26 more

Open access · goldAbstract read
In one paragraph

Article in Life (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors at 8 institutions in 2 countries.

Steven Van VoorenUgenTec, Inc., Cambridge, MA 02138, USA.
James GraysonUgenTec, Inc., Cambridge, MA 02138, USA.
Marc Van RanstDepartment of Microbiology, Immunology and Transplantation, KU Leuven, B-3000 Leuven, Belgium.
Elisabeth DequekerClinical Department of Laboratory medicine and National Reference Center for Respiratory Pathogens, University Hospitals Leuven, B-3000 Leuven, Belgium.
Lies LaenenDepartment of Microbiology, Immunology and Transplantation, KU Leuven, B-3000 Leuven, Belgium.ORCID 0000-0001-9118-8608
Reile JanssenClinical Department of Laboratory medicine and National Reference Center for Respiratory Pathogens, University Hospitals Leuven, B-3000 Leuven, Belgium.
Laurent GilletDepartment of Microbiology, University of Liège, B-4000 Liège, Belgium.ORCID 0000-0002-1047-2525
Fabrice BureauDepartment of Microbiology, University of Liège, B-4000 Liège, Belgium.
Wouter CoppietersDepartment of Microbiology, University of Liège, B-4000 Liège, Belgium.
Nathalie DevosGSK Vaccines, B-1330 Rixensart, Belgium.
Benjamin HengchenGSK Vaccines, B-1330 Rixensart, Belgium.
Pierre WattiauGSK Vaccines, B-1330 Rixensart, Belgium.ORCID 0000-0003-4737-5080
Sibylle MéhaudenGSK Vaccines, B-1330 Rixensart, Belgium.
Yvan VerlindenJanssen Pharmaceutica N.V., Johnson & Johnson, B-2340 Beerse, Belgium.
Kurt Van BaelenJanssen Pharmaceutica N.V., Johnson & Johnson, B-2340 Beerse, Belgium.
Theresa PatteryJanssen Pharmaceutica N.V., Johnson & Johnson, B-2340 Beerse, Belgium.
Jean-Pierre ValentinUCB Pharma, B-1420 Braine l'Alleud, Belgium.
Kris JanssenUCB Pharma, B-1420 Braine l'Alleud, Belgium.
Martine GeraertsUCB Pharma, B-1420 Braine l'Alleud, Belgium.
John SmeragliaUCB Pharma, B-1420 Braine l'Alleud, Belgium.
Jan HellemansBiogazelle, Technologiepark Zwijnaarde, B-9052 Zwijnaarde, Belgium.ORCID 0000-0003-0825-0031
Pieter WytynckBiogazelle, Technologiepark Zwijnaarde, B-9052 Zwijnaarde, Belgium.ORCID 0000-0002-8712-4051
Pieter MestdaghBiogazelle, Technologiepark Zwijnaarde, B-9052 Zwijnaarde, Belgium.
Nienke BesbruggeBiogazelle, Technologiepark Zwijnaarde, B-9052 Zwijnaarde, Belgium.
René HöferBiogazelle, Technologiepark Zwijnaarde, B-9052 Zwijnaarde, Belgium.
Friedel NolletBiogazelle, Technologiepark Zwijnaarde, B-9052 Zwijnaarde, Belgium.
Jo VandesompeleBiogazelle, Technologiepark Zwijnaarde, B-9052 Zwijnaarde, Belgium.ORCID 0000-0001-6274-0184
Pieter De SmetCliniSys|MIPS, B-9000 Ghent, Belgium.
John LebonCliniSys|MIPS, B-9000 Ghent, Belgium.
Emmanuel VandewynckeleCliniSys|MIPS, B-9000 Ghent, Belgium.
Steven VerstrepenCliniSys|MIPS, B-9000 Ghent, Belgium.
Wouter UtenUgenTec n.v., B-3500 Hasselt, Belgium.
Arnaud CapronSciensano, Belgian Institute for Health, B-1050 Brussels, Belgium.
Hugues MalonneFederal Agency for Medicines and Health Products (FAGG-AFMPS), B-1210 Brussels, Belgium.
Jeroen PoelsFederal Agency for Medicines and Health Products (FAGG-AFMPS), B-1210 Brussels, Belgium.
Emmanuel AndréDepartment of Microbiology, Immunology and Transplantation, KU Leuven, B-3000 Leuven, Belgium.
KU Leuven · BEGlaxoSmithKline (Belgium) · BEUCB Pharma (Belgium) · BEJohnson & Johnson (United States) · USUniversity of Liège · BEEurogentec (Belgium) · BESciensano (Belgium) · BEUniversité Libre de Bruxelles · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present our approach to rapidly establishing a standardized, multi-site, nation-wide COVID-19 screening program in Belgium. Under auspices of a federal government Task Force responsible for upscaling the country's testing capacity, we were able to set up a national testing initiative with readily available resources, putting in place a robust, validated, high-throughput, and decentralized qPCR molecular testing platform with embedded proficiency testing. We demonstrate how during an acute scarcity of equipment, kits, reagents, personnel, protective equipment, and sterile plastic supplies, we introduced an approach to rapidly build a reliable, validated, high-volume, high-confidence workflow based on heterogeneous instrumentation and diverse assays, assay components, and protocols. The workflow was set up with continuous quality control monitoring, tied together through a clinical-grade information management platform for automated data analysis, real-time result reporting across different participating sites, qc monitoring, and making result data available to the requesting physician and the patient. In this overview, we address challenges in optimizing high-throughput cross-laboratory workflows with minimal manual intervention through software, instrument and assay validation and standardization, and a process for harmonized result reporting and nation-level infection statistics monitoring across the disparate testing methodologies and workflows, necessitated by a rapid scale-up as a response to the pandemic.

Indexed as

data analysishigh-throughput testinglab automationqc monitoringqPCRSARS-CoV-2

Identifiers

PMID35207446
PMCPMC8879918
OpenAlexW4205956363

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.